Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA)

JERUSALEM, October 25, 2011 /PRNewswire via COMTEX/ –Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://chinese.oramed.com), a developer of oral drug delivery systems, announced today that its work entitled “Evaluation of the Safety and Efficacy of Two Oral Insulin Formulations in Healthy Volunteers” will be presented at the […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals Announces Successful Phase 1 Clinical Trial Results for EnteraBio

JERUSALEM, September 27, 2011 /PRNewswire via COMTEX/ –Oramed Pharmaceuticals Inc. (OTC BB: ORMP) (http://chinese.oramed.com), a developer of oral delivery systems, announced that EnteraBio Ltd. recently reported successful Phase 1 clinical trial results. The Phase 1 data supports the continued development of Entera’s oral osteoporosis drug.

Entera’s […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011

JERUSALEM, September 15, 2011 /PRNewswire via COMTEX/ –Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (http://chinese.oramed.com), a developer of oral delivery systems, announced today that Ehud Arbit, M.D., the Director of R&D at Oramed, is scheduled to present at the 8th Annual Israel Strategic Partner and Venture […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals to Present at Rodman & Renshaw 13th Annual Global Investment Conference

JERUSALEM, September 8, 2011 /PRNewswire via COMTEX/ –Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (http://chinese.oramed.com), a developer of oral delivery systems, announced today that Roy Eldor, M.D., the Director of Medical Affairs at Oramed, is scheduled to present at the Rodman & Renshaw 13th Annual Global […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board

JERUSALEM, Israel, June 22, 2011 /PRNewswire via COMTEX/ –Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a biotech company
with a novel platform technology for the oral delivery of drugs
currently only available via injection, announced today that Dr.
Michael Berelowitz, M.D., has been appointed the Chairman of its
Scientific Advisory Board […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals to Present at The 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CHODy), China 2011

Oramed to Present on Friday June 3, 2011

JERUSALEM, May 18, 2011 /PRNewswire via COMTEX/ –Oramed Pharmaceuticals
Inc. (OTCBB: ORMP.OB) (http://chinese.oramed.com), a developer of oral delivery
systems, announced today that it was chosen to present at The 1st Asia
Pacific Congress on Controversies to Consensus in Diabetes, Obesity and
Hypertension […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals to Present at the 10th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2011

Oramed to Present on Tuesday, May 24, 2011 at 12:50 p.m. (IDT)

JERUSALEM, May 11, 2011 /PRNewswire via COMTEX/ –Oramed Pharmaceuticals
Inc. (OTCBB: ORMP.OB) (http://chinese.oramed.com), a developer of oral delivery
systems, announced today that it was chosen to present at the 10th National
Life Science & Technology Week ILSI-BIOMED […]

Categories: 新闻通稿|Tags: |

Oramed Successfully Completes Toxicity Study for ORMD-0801

JERUSALEM, March 23, 2011 /PRNewswire via COMTEX/ –Oramed
Pharmaceuticals Inc. (OTC: ORMP), a developer of oral delivery systems,
announced today that it has successfully completed a comprehensive toxicity
study for its flagship oral insulin capsule, ORMD-0801. The study was
completed under conditions prescribed by the United States Food and […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals Announces Completion of $3.4 Million Private Placement Round

JERUSALEM, March 9, 2011 /PRNewswire via COMTEX/ –Oramed Pharmaceuticals
Inc. (OTC: ORMP) (http://chinese.oramed.com), a developer of oral delivery
systems, announced today that it has completed a capital raise of $3,356,000
in a private placement of 10,487,500 shares of its common stock with a select
group of investors. The private […]

Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals Sells its Stake in Entera Bio for $1.15 Million; Buyer Also to Invest $250,000 in Oramed

JERUSALEM, February 28, 2011 /PRNewswire via COMTEX/ –Oramed
Pharmaceuticals Inc. (OTCBB: ORMP), a developer of oral drug delivery
systems, announced today that its subsidiary Oramed Ltd. entered into a Share
Purchase Agreement with D.N.A Biomedical Solutions Ltd. (formerly Laser
Detect Systems Ltd.), an Israeli company listed on the Tel […]

Categories: 新闻通稿|Tags: |